JoÃ£o M FrazÃ£o

List of Publications by Year
in descending order

57 papers	2,976 citations	331259 21 h-index	182168 51 g-index
57 all docs	57 docs citations	57 times ranked	2829 citing authors

#	Article	IF	Citations
1	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. New England Journal of Medicine, 2012, 367, 2482-2494.	13.9	805
2	Bonsai: an event-based framework for processing and controlling data streams. Frontiers in Neuroinformatics, 2015, 9, 7.	1.3	389
3	The OPTIMA Study. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 36-45.	2.2	202
4	A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney International, 2000, 58, 436-445.	2.6	162
5	Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 405-412.	3.0	153
6	Intermittent doxercalciferol (1Î±-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism. American Journal of Kidney Diseases, 2000, 36, 550-561.	2.1	118
7	Low Bone Volumeâ€"A Risk Factor for Coronary Calcifications in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 450-455.	2.2	95
8	Dietary magnesium supplementation preventsÂandÂreverses vascular and soft tissueÂcalcifications in uremic rats. Kidney International, 2017, 92, 1084-1099.	2.6	85
9	Validating silicon polytrodes with paired juxtacellular recordings: method and dataset. Journal of Neurophysiology, 2016, 116, 892-903.	0.9	81
10	Does Impedance Matter When Recording Spikes With Polytrodes?. Frontiers in Neuroscience, 2018, 12, 715.	1.4	74
11	Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2008, 23, 3731-3737.	0.4	62
12	Hypokinetic azotemic osteodystrophy. Kidney International, 1998, 54, 1000-1016.	2.6	48
13	Intermittent oral 1&agr;-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrology Dialysis Transplantation, 1998, 13, 68-72.	0.4	46
14	Adynamic bone disease: clinical and therapeutic implications. Current Opinion in Nephrology and Hypertension, 2009, 18, 303-307.	1.0	43
15	Calcimimetic agents: Review and perspectives. Kidney International, 2003, 63, S91-S96.	2.6	37
16	Calcium-sensing receptor and calcimimetic agents. Kidney International, 1999, 56, S52-S58.	2.6	36
17	Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney International, 2019, 95, 1064-1078.	2.6	33
18	Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. CKJ: Clinical Kidney Journal, 2018, 11, 80-88.	1.4	32

#	Article	IF	Citations
19	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	1.4	29
20	RAPOSA: Semi-Autonomous Robot for Rescue Operations. , 2006, , .		27
21	Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study. BMJ Open, 2015, 5, e006897-e006897.	0.8	24
22	The calcimimetic agents: Perspectives for treatment. Kidney International, 2002, 61, S149-S154.	2.6	22
23	Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects. Nephron Clinical Practice, 2012, 120, c108-c119.	2.3	22
24	Calciphylaxis: from the disease to the diseased. Journal of Nephrology, 2015, 28, 531-540.	0.9	21
25	Cortical bone analysis in a predialysis population: a comparison with a dialysis population. Journal of Bone and Mineral Metabolism, 2017, 35, 513-521.	1.3	21
26	Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4. CKJ: Clinical Kidney Journal, 2021, 14, 2401-2408.	1.4	21
27	A search and rescue robot with teleâ€operated tether docking system. Industrial Robot, 2007, 34, 332-338.	1.2	20
28	Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clinical Nephrology, 2011, 76, 233-243.	0.4	19
29	Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. Osteoporosis International, 2010, 21, 619-625.	1.3	18
30	The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. Clinica Chimica Acta, 2020, 508, 221-227.	0.5	18
31	Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Failure Reviews, 2021, 26, 891-896.	1.7	17
32	Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney International, 2008, 74, S38-S43.	2.6	16
33	The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives. Journal of Nephrology, 2016, 29, 617-626.	0.9	16
34	Evolution of bone disease after kidney transplantation: A prospective histomorphometric analysis of trabecular and cortical bone. Nephrology, 2016, 21, 55-61.	0.7	15
35	Parathyroidectomy in Persistent Post-transplantation Hyperparathyroidism â€" Single-center Experience. Transplantation Proceedings, 2017, 49, 795-798.	0.3	13
36	Epstein-Barr-virus-induced interstitial nephritis in an HIV-positive patient with progressive renal failure. Nephrology Dialysis Transplantation, 1998, 13, 1849-1852.	0.4	12

#	Article	IF	Citations
37	Calcitriol in the Management of Renal Osteodystrophy. Seminars in Dialysis, 1996, 9, 316-325.	0.7	12
38	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). CKJ: Clinical Kidney Journal, 2015, 8, 567-571.	1.4	12
39	Influence of gender and age on haemodialysis practices: a European multicentre analysis. CKJ: Clinical Kidney Journal, 2020, 13, 217-224.	1.4	12
40	Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients. PLoS ONE, 2017, 12, e0179868.	1.1	11
41	Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?. BMC Nephrology, 2012, 13, 76.	0.8	9
42	Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2008, 23, 2889-2894.	0.4	8
43	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Revista Portuguesa De Cardiologia, 2020, 39, 517-541.	0.2	8
44	Impact of Vitamin D Dose on Biochemical Parameters in Patients with Secondary Hyperparathyroidism Receiving Cinacalcet. Nephron Clinical Practice, 2009, 112, c41-c50.	2.3	7
45	Achievement of renal anemia KDIGO targets by two different clinical strategies â€“ a European hemodialysis multicenter analysis. BMC Nephrology, 2019, 20, 5.	0.8	7
46	Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients. PLoS ONE, 2021, 16, e0258284.	1.1	7
47	The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder. Nefrologia, 2013, 33, 835-44.	0.2	7
48	Cardiovascular risk in dialysis patients: an X-ray vision on vascular calcifications. Kidney International, 2008, 74, 1505-1507.	2.6	6
49	Efficacy and safety of calcium carbonate in normophosphataemic patients with chronic kidney disease Stages 3 and 4. CKJ: Clinical Kidney Journal, 2021, 14, 550-555.	1.4	6
50	Evaluation of Renal Osteodystrophy and Serum Bone-Related Biomarkers in a Peritoneal Dialysis Population. Journal of Bone and Mineral Research, 2020, 37, 1689-1699.	3.1	6
51	Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy. CKJ: Clinical Kidney Journal, 2008, 1, i12-i17.	1.4	4
52	Could Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?â€”A Proof-of-Concept Study. Journal of Clinical Medicine, 2022, 11, 457.	1.0	2
53	Symptomatic hypercalcemia in a diabetic patient undergoing continuous ambulatory peritoneal dialysis: Value of bone biopsy in the diagnosis and management. American Journal of Kidney Diseases, 1995, 26, 831-835.	2.1	0
54	FP416PHOSPHATE RESTRICTION PRESERVES BONE VOLUME IN EARLY AND LATE STAGES OF CKD IN RATS. Nephrology Dialysis Transplantation, 2015, 30, iii209-iii209.	0.4	0

#	Article	IF	Citations
55	P1514PERIPHERIAL VASCULAR DISEASE IN DIABETIC PATIENTS ON HEMODIALYSIS - RISK OF HOSPITALIZATION AND MORTALITY IN A LARGE EUROPEAN COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
56	Improvements in six aspects of quality of care of incident hemodialysis patients â€“ a real-world experience. BMC Nephrology, 2021, 22, 333.	0.8	0
57	The Role of the Old and the New Calcimimetic Agents in Chronic Kidney Disease-Mineral and Bone Disorder. , 2020, , 155-173.		0